Formulation, Optimization, And In Vitro Evaluation Of Nifedipine Matrix-Based Transdermal Patches For Controlled Management Of Hypertension

Hypertension remains one of the most prevalent chronic cardiovascular disorders globally, acting as a primary risk factor for stroke, myocardial infarction, and renal failure. Effective management of blood pressure requires consistent, long-term pharmacological intervention to prevent life-threatening complications. Nifedipine, a potent dihydropyridine calcium channel blocker, is widely utilized as a first-line treatment due to its efficacy in inducing peripheral vasodilation and reducing systemic vascular resistance.

However, the therapeutic utility of conventional oral Nifedipine is significantly hampered by its short biological half-life and extensive first-pass hepatic metabolism, which results in low systemic bioavailability. Furthermore, oral administration often leads to rapid fluctuations in plasma drug concentrations, necessitating frequent dosing and increasing the risk of side effects such as reflex tachycardia and peripheral edema. These limitations often culminate in poor patient adherence, which is a critical barrier to successful hypertension management.

To overcome these challenges, Transdermal Drug Delivery Systems (TDDS) have gained considerable attention as a sophisticated alternative to oral and parenteral routes. By delivering the medication through the skin surface into the systemic circulation, TDDS bypasses the gastrointestinal environment and hepatic first-pass effect. This route offers a controlled and sustained release profile, maintaining stable therapeutic plasma levels over an extended period. For patients with hypertension, this stability is vital to ensure 24-hour blood pressure control and to minimize the "peak-and-valley" effect associated with oral bolus doses.

The performance of a transdermal patch is heavily dependent on the composition of its polymeric matrix, which dictates the rate of drug diffusion and the mechanical integrity of the system. Recent pharmaceutical research has shifted toward the integration of diverse polymer blends to fine-tune release kinetics. Matrix-based systems are particularly favored for their simplicity, stability, and ease of manufacturing. By optimizing the ratio of hydrophilic and hydrophobic polymers, it is possible to engineer a delivery vehicle that ensures a predictable and constant flux of Nifedipine.

The present study aims to design, formulate, and optimize Nifedipine matrix-based transdermal patches to enhance the management of hypertension. Utilizing a systematic approach, various formulation parameters were evaluated to identify the ideal polymer-plasticizer combination. The developed patches underwent rigorous in vitro evaluation, including physicochemical characterization, drug-excipient compatibility studies, and skin permeation kinetics, to ensure a sustained therapeutic effect and improved patient compliance.

2. MATERIALS AND METHODS

2.1. Materials

Nifedipine was procured from Yarrow Chem Products, Mumbai, India. The polymers used for the matrix fabrication, including Hydroxypropyl Methylcellulose (HPMC K100) and Ethyl Cellulose (EC), were obtained from Finar Chemicals Ltd., India. Polyvinylpyrrolidone (PVP K30) was sourced from Prasol Chemicals Pvt. Ltd., India. Propylene glycol, acting as a plasticizer, and Oleic acid, utilized as a chemical permeation enhancer, were both purchased from Qualikems Fine Chem Pvt. Ltd., India. All other reagents and solvents employed in the study were of analytical grade.

 2.2. Method of Preparation

The transdermal patches are prepared using the solvent casting technique. The polymers (HPMC K100, Ethyl Cellulose, and PVP K30) are dissolved in a suitable solvent system. Nifedipine is then incorporated into the polymeric solution under constant stirring. Propylene glycol and Oleic acid are added to the mixture to ensure flexibility and enhanced skin permeation, respectively. The resulting medicated solution is cast onto a backing membrane and dried at room temperature to obtain a uniform matrix-type patch.

Formulation of Nifedipine matrix patch:

Matrix-type transdermal patches containing Nifedipine were prepared using the solvent  casting method. A total of nine formulations were developed by varying the ratios of  polymers and permeation enhancers. Accurately weighed quantities of the selected  polymers (HPMC K100, Ethyl Cellulose, and PVP K30) were dissolved in a suitable  solvent system consisting of methanol and chloroform, and the solution was stirred  continuously for 10–15 minutes to ensure complete dissolution. Subsequently, the  accurately weighed amount of Nifedipine was added to the polymeric solution and mixed  thoroughly using a magnetic stirrer or vortex mixer to achieve uniform drug dispersion.  To this mixture, a calculated quantity of propylene glycol (as plasticizer) and permeation  enhancers (oleic acid and Tween 80) were added, followed by further stirring to obtain a  homogeneous casting solution. The final solution was carefully poured into a Petri dish lined with aluminum foil and allowed to dry at room temperature for 24 hours to facilitate  slow and uniform solvent evaporation. After complete drying, the formed films were carefully removed and cut into uniform patches of 1 cm². The prepared patches were   stored in a desiccator under controlled conditions until further evaluation.

Figure.2. Process flow and characterization scheme for nifedipine TDDS Patch

Table: 1 Quantitative Composition of Nifedipine TDDS Formulation:

3. PHYSICOCHEMICAL EVALUATION OF TRANSDERMAL PATCHES

3.1. Physical Appearance and Morphological Characteristics

The formulated transdermal patches were visually inspected for colour, clarity, flexibility, and surface smoothness. The presence of any suspended particulate matter, air bubbles, or physical imperfections was examined by observing the patches against both white and black backgrounds. The overall appearance and uniformity of the patches were carefully evaluated.

3.2. Weight Uniformity and Thickness

Weight Variation

Ten patches were randomly selected from each formulation batch and weighed individually using a calibrated electronic balance. The average weight was calculated, and the individual weights were compared with the mean value to assess batch-to-batch uniformity and consistency.

Thickness

The thickness of the transdermal patches was measured at three different points using a digital screw gauge or micrometer. The mean thickness value was calculated for each formulation to ensure uniformity of the film, which is essential for consistent drug loading and controlled drug release.

3.3. Mechanical Strength and Folding Endurance

The mechanical strength and flexibility of the prepared patches were evaluated by determining the folding endurance. A strip of film measuring 4×3 cm was repeatedly folded at the same position until it broke. The number of folds required to cause breakage was recorded as the folding endurance value, indicating the mechanical stability and flexibility of the patch during handling and application.

3.4. Moisture Analysis

Percentage Moisture Content

The prepared patches were weighed individually to obtain the initial weight (Wi​) and placed in a desiccator containing fused calcium chloride at 40∘C for 24 hours. The patches were then reweighed until a constant final weight (Wf​) was obtained. The percentage moisture content was calculated using the following equation:

% Moisture Content=(Wi−Wf/Wf)×100

Percentage Moisture Uptake

To evaluate the physical stability of the patches under humid conditions, the patches were exposed to 84% relative humidity in a desiccator containing a saturated potassium chloride solution. After 72 hours, the patches were removed and weighed. The percentage moisture uptake was calculated based on the increase in weight.

% Moisture Uptake=(Final Weight−Initial Weight/Initial Weight)×100

3.5. Drug Content Uniformity

A patch of known area (3.83cm²) was dissolved in phosphate-buffered saline (PBS, pH 7.4) containing ethanol and dichloromethane to ensure complete dissolution of the polymer matrix. The final volume was adjusted appropriately, and the resulting solution was filtered and diluted. The absorbance was measured using a UV-visible spectrophotometer at the specified λmax​. The drug content was calculated by applying the appropriate dilution factor.

4. IN VITRO DRUG RELEASE STUDIES

USP Apparatus V (Paddle-over-Disc Method)

Experimental Setup

The in vitro drug release study was carried out using USP Apparatus V (Paddle-over-Disc method). The prepared transdermal patch was fixed onto a glass plate and immersed in 500mL of phosphate buffer solution (pH 7.4), maintained at 32±0.5∘C32 \pm 0.5^\circ\text{C}32±0.5∘C.

Procedure

The paddle was maintained at a height of approximately 2.5 cm above the patch surface and rotated at 50 rpm. At predetermined time intervals over a period of 24 hours, 5 mL aliquots were withdrawn and replaced with an equal volume of fresh dissolution medium to maintain sink conditions. The collected samples were analyzed spectrophotometrically, and the cumulative percentage drug release was calculated.

5. MATHEMATICAL MODELING OF DRUG RELEASE KINETICS

To elucidate the mechanism of drug release from the transdermal patches, the in vitro release data were fitted into different kinetic models, including Zero-order, First-order, Higuchi, and Korsmeyer–Peppas models.

Zero-Order Kinetics

The zero-order model describes a system where drug release is independent of drug concentration.

Q=K0t

Where:

• Q = Amount of drug released at time t
• K₀​ = Zero-order release rate constant

First-Order Kinetics

The first-order model describes concentration-dependent drug release.

ln (100−Q)=ln(100)−K₁t

 Where:

• Q = Percentage drug released at time t
• K₁​ = First-order release rate constant

Higuchi Model

The Higuchi model explains drug release from a matrix system through diffusion.

Q=K_H​^t1/2

Where:

• Q = Amount of drug released at time t
• K_H​ = Higuchi dissolution constant

Korsmeyer–Peppas Model

The Korsmeyer–Peppas model is used to determine the mechanism of drug release from polymeric systems.

Mt/M∞= K_m​tⁿ

Where:

• Mt​ = Amount of drug released at time t
• M∞​ = Total amount of drug released
• K_m​ = Kinetic constant
• n = Diffusion exponent indicating the mechanism of drug release

Interpretation of the diffusion exponent (n)(n)(n):

• n=0.45: Fickian diffusion
• 0.45<n<0.89: Non-Fickian (anomalous) transport
• n=0.89: Case II transport (zero-order release)

Results and Discussion

Preformulation Studies of Drug

Table 2: Analytical report for Nifedipine :

Interpretation:

The observed physicochemical properties were consistent with reported standards, confirming the identity and purity of the drug. The melting point and solubility profile indicate suitability for transdermal formulation development.

Evaluation of Transdermal Patches

Figure 3: FT-IR spectra for Nifedipine and Polymers

Table 3. Physico chemical properties of transdermal patch of Nifedipine:

Reported as mean ± S.D. (n=3)

Table.4. In-vitro drug release studies of transdermal patch of Nifedipine:

Figure.4. In vitro release profile of Transdermal Patch of Nifedipine (NFP1-NFP9)

Drug Release Kinetics of Optimized Formulation (F5)

Based on the R² values, your formulation F5 fits the Higuchi Model best (R² = 0.995). Since the Peppas 'n' value is approximately 0.61, you can conclude that the drug release follows Anomalous (Non-Fickian) Transport, meaning the release is controlled by both diffusion and a slight swelling/erosion of the HPMC matrix.

The combined kinetic analysis indicated that the optimized formulation follows Higuchi kinetics with non-Fickian diffusion behavior, suggesting a controlled drug release mechanism governed by both diffusion and polymer relaxation.